➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Mallinckrodt
Merck
McKinsey
Johnson and Johnson

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AZD1775

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AZD1775?

AZD1775 is an investigational drug.

There have been 51 clinical trials for AZD1775. The most recent clinical trial was a Phase 2 trial, which was initiated on March 13th 2017.

The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Dana-Farber Cancer Institute.

There are thirteen US patents protecting this investigational drug and one hundred and thirty-three international patents.

Recent Clinical Trials for AZD1775
TitleSponsorPhase
A Study of Adavosertib as Treatment for Uterine Serous CarcinomaParexelPhase 2
A Study of Adavosertib as Treatment for Uterine Serous CarcinomaAstraZenecaPhase 2
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction CancersNational Cancer Institute (NCI)Phase 1

See all AZD1775 clinical trials

Clinical Trial Summary for AZD1775

Top disease conditions for AZD1775
Top clinical trial sponsors for AZD1775

See all AZD1775 clinical trials

US Patents for AZD1775

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD1775   Start Trial Methods and compositions for treatment of cancer and autoimmune disease THE JACKSON LABORATORY (Bar Harbor, ME)   Start Trial
AZD1775   Start Trial Systems and methods for treating cancer Dignity Health (San Francisco, CA) The Translational Genomics Research Institute (Phoenix, AZ)   Start Trial
AZD1775   Start Trial Substituted pyrazolo[3,4-d]pyrimidinone derivatives Banyu Pharmaceutical Co., Ltd. (Chiyoda-Ku, Tokyo, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Mallinckrodt
Merck
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.